Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
NCT ID: NCT00099879
Last Updated: 2010-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
NCT00359450
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
NCT01024062
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
NCT00461110
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
NCT00103831
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
NCT01820325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-275183
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease
* Adequate hematologic, hepatic and renal functions
* ECOG Performance Status of 0-2
Exclusion Criteria
* Recent significant cardiovascular disease
* Woman who are pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Sacramento, California, United States
Local Institution
New Haven, Connecticut, United States
Local Institution
Atlanta, Georgia, United States
Local Institution
Maywood, Illinois, United States
Local Institution
Detroit, Michigan, United States
Local Institution
Pittsburgh, Pennsylvania, United States
Local Institution
Nashville, Tennessee, United States
Local Institution
Brussels, , Belgium
Local Institution
Leuven, , Belgium
Local Institution
Besançon, Cedex, France
Local Institution
Saint-Herblain, Cedex, France
Local Institution
Belfort, , France
Local Institution
Parma, , Italy
Local Institution
Roma, , Italy
Local Institution
Amsterdam, , Netherlands
Local Insitution
Groningen, , Netherlands
Local Institution
Barcelona, , Spain
Local Institution
Madrid, , Spain
Local Institution
Shefield, Yorkshire, United Kingdom
Local Institution
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA165-020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.